Influence of Oxytocin on the Startle Reflex and on Its Modulation
NCT01066299 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2011-11-29
Summary
Oxytocin (OXT) is currently regarded as a crucial neuropeptide in the mediation of various human social behaviors, e.g. social affiliation, social recognition, and the modulation of anxiety, mood, and aggression. An impairment of social behavior, emotional regulation as well as increased stress reactions are characteristic of several psychiatric conditions, including schizophrenia, social anxiety and PTSD, in which there is also some evidence for OXT dysfunction. The startle reflex is a basic defensive reaction that can be modulated by emotional stimuli. The investigation of the startle reflex and of its modulation is a well-validated method to test stress reactions and emotional regulation. These processes are impaired in the same psychiatric diseases, in which OXT dysfunction was evidenced. Although previous animal studies showed that the dysfunction of brain OXT systems might be implicated in startle reflex and in its modulation, no study has been performed yet in human that investigated the influence of OXT administration on the startle response and on its affective modulation. A first aim of this study is to investigate the influence of OXT on stress reactivity and emotional modulation in healthy humans. A second aim is to develop a method for the investigation of anxiety disorders. Fifty male healthy participants will be tested using a randomized double-blind placebo-controlled cross-over design in two occasions; once with administration of 24 IU OXT, and once with placebo using nasal sprays while performing a computer-based experiment, in which emotional pictures and auditory startle probes are presented. We will measure the subject's subjective ratings of the pictures as well as the facial EMG activation, heart rate and electrodermal activation throughout the study. This project offers a unique opportunity to study the relationship between the OXT system and basic motivational and emotional behaviors. The investigation of these mechanisms is in turn greatly worthwhile, not only for understanding of the neurochemical and physiological processes involved in emotional regulation, but also for the comprehension of the neuroendocrine and neurophysiological mechanismsunderlying anxiety disorders. In the long term, it could open the possibilities of OXT as a psychobiological therapeutics of psychiatric disorders.
Conditions
- Psychiatric Disorders
Interventions
- DRUG
-
Syntocinon®
single dose of OXT (24 IU)
- DRUG
-
inactive nasal spray
single dose (24 IU)
Sponsors & Collaborators
-
University of Basel
collaborator OTHER -
University of Freiburg
collaborator OTHER -
University of Zurich
lead OTHER
Principal Investigators
-
Chantal Martin Soelch, PhD · University Hospital Zurich, Division of Psychiatry and Psychotherapy
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2012-09-30
- Completion
- 2012-12-31
Countries
- Switzerland
Study Locations
More Related Trials
-
Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy
NCT05383300 ·Status: COMPLETED ·Phase: NA
-
Oxytocin Add-on Study for Stable Anxiety Patients
NCT00989937 ·Status: TERMINATED ·Phase: NA
-
Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness
NCT06332066 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039 ·Status: RECRUITING ·Phase: NA
-
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
NCT02922166 ·Status: UNKNOWN ·Phase: PHASE1
-
Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety
NCT03085654 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy of Nitrous Oxide in OCD: Pilot Study
NCT03826693 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder
NCT02384369 ·Status: WITHDRAWN ·Phase: PHASE2
-
Trait Anxiety and Defensive Networks
NCT02682888 ·Status: COMPLETED ·Phase: NA
-
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects
NCT00700076 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
NCT02066792 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
NCT04623099 ·Status: RECRUITING ·Phase: PHASE4
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
NCT05232032 ·Status: RECRUITING ·Phase: PHASE2
-
Psychopharmacology of Fear-Potentiated Startle in Humans
NCT00044096 ·Status: COMPLETED
-
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders
NCT03153579 ·Status: COMPLETED ·Phase: PHASE2
-
Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania
NCT02059980 ·Status: COMPLETED ·Phase: NA
-
Generalization of Extinction Learning
NCT01900301 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety
NCT03346239 ·Status: COMPLETED ·Phase: NA
-
Threat-Avoidance Learning in Anxiety Patients
NCT02336802 ·Status: UNKNOWN
-
Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder
NCT01949753 ·Status: UNKNOWN ·Phase: PHASE2
-
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
NCT00748956 ·Status: COMPLETED ·Phase: PHASE2
-
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder
NCT04071600 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT03239210 ·Status: COMPLETED ·Phase: PHASE4
-
Affect-regulatory Characteristics of Deceptive Placebos
NCT05372744 ·Status: COMPLETED ·Phase: NA
-
Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
NCT00131339 ·Status: COMPLETED ·Phase: NA